9 news items
SAB Biotherapeutics Announces Departure of Chief Financial Officer
SABS
30 May 24
that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
SABS
21 May 24
of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
SABS
20 May 24
report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
SABS
6 May 24
provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may
SAB Biotherapeutics Provides SAB-142 Trial Update
SABS
16 Apr 24
statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally
b1p931wbe78bnv8gepz pugv
SABS
8 Apr 24
under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may
ff8mb 3zr
SABS
4 Apr 24
that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act
0djc53gvn7lv22knfs
SABS
29 Mar 24
of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words
dwblxde cyq02shnm85x7djovyr8u3l1n
SABS
25 Mar 24
harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words
- Prev
- 1
- Next